Bromodomain inhibitors

A method of treating prostate cancer in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the compound of Formula (I) has the following structure:

• wherein:
• R2 is selected from CH3, CH2CH3, CH2CF3, CH2F, CHF2, CF3, CH2D, CHD2, or CD3;
• X5 is C—R5 or N;
• X6 is C—R6 or N;
• X7 is C—R7 or N;
• X8 is C—R8 or N;
• wherein no more than two of X5, X6, X7, or X8 may be N;
• R5 is hydrogen, halogen, —CN, —NHR61, —N(R61)2, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, wherein each R61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R6 is hydrogen, halogen, —CN, —NHR61, —N(R61)2, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, wherein each R61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R7 is hydrogen, halogen, —CN, —NHR61, —N(R61)2, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, wherein each R61 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• R8 is hydrogen, halogen, or alkyl;
• RA is
• X2 is N or C—R12, wherein R12 is hydrogen, halogen, alkyl, or alkoxy;
• R13 is —Y—Z;
• Y is selected from a bond, —CH2—, or —CH(C1-C4 alkyl)-;
• Z is selected from —SO2R21, —N(R22)SO2R21, —SO2N(R22)2, —N(R22)SO2N(R22)2, —CON(R22)2, —N(R22)CO2R21, —N(R22)CON(R22)2, —N(R22)COR21, —COR21, —OC(O)N(R22)2, —OSO2N(R22)2, or —N(R22)SO3R21;
• X3 is N or C—R14, wherein R14 is hydrogen, halogen, —CN, alkyl, cycloalkyl, or alkoxy;
• X4 is N or C—R15, wherein R15 is hydrogen, halogen, alkyl, —CN, or alkoxy;
• R16 is hydrogen, halogen, —N(H)COX, or —W—X, wherein W is a bond, —O—, —S—, or —NH—, and X is selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkynyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• and
• each R22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl.